

Description

15-epi-Lipoxin A₄ (15-epi-LXA₄) is an aspirin-triggered eicosanoid believed to be involved in the positive attributes of aspirin therapy for heart, cancer, and human immunodeficiency virus patients. During inflammation, neutrophils are activated. 15-epi-LXA₄, when administered in vivo, inhibits neutrophil activation and dampens inflammation (Takano, 1997). 15-epi-LXA₄ is naturally formed in the body via this pathway: Arachidonic Acid (AA) → 15(R)-HETE → 15-epi-LXA₄. Aspirin is thought to be involved in the acetylation of prostaglandin G/H synthase, which triggers the conversion of AA to 15(R)-HETE.

This assay, which is both sensitive and selective for 15-epi-LXA₄, is essential to researchers studying anti-inflammatory medications.

Kit Contents

- 15-epi-LXA₄ Antibody-Coated Microplate (96 well)
- 15-epi-LXA₄ Standard
- 15-epi-LXA₄ Conjugate, Lyophilized (HRP)
- K-Blue Substrate
- EIA Buffer
- Wash Buffer (10x)
- Extraction Buffer (5x)
- Instruction Booklet

Cross-reactivity

15-epi-Lipoxin A ₄	100.0%
Lipoxin A ₄	3.00%
15(R)-HETE	0.8%
5(S)-HETE	<0.01%
12(S)-HETE	<0.01%
15(S)-HETE	<0.01%

Specifications

Sensitivity:	
80% B/B ₀	0.05 ng/mL
50% B/B ₀	0.2 ng/mL
Assay Range	0.02 – 2.0 ng/mL
Inter-Assay CV	≤ 10%
Intra-Assay CV	≤ 10%
Size	96 well microplate
Assay Sample Size	50 µL
Total Assay Incubation Time	1.5 hours
Wavelength	650 nm, 450 nm with acid stop
Storage Conditions	-20°C for lyophilized conjugate, 4°C for all other kit components
Antibody	Polyclonal, Rabbit

Research use only

Neogen Corporation

800/477-8201 (USA/Canada) • 859/254-1221

E-mail: inform@neogen.com